Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of the COVID-19 vaccine developer have been on fire in 2020. ,

Why Inovio Stock Soared 83% in June

The competition for a Covid-19 vaccine is intense. Inovio needs to provide investors with more information to give INO stock a chance at long-term upside.

Inovio Pharmaceuticals Comes Up Short in Phase 1

Is now a good time to get in on this biotech stock?

Inovio Stock: Buy, Sell, or Hold?

Investors seem to think a 37% drop this week presents a good opportunity to buy the biotech stock.

Why Inovio Pharmaceuticals Stock Is Bouncing Back Today

Blue Apron

Lululemon Athletica

Nikola

Novavax

Overstock.com

Peloton

Shopify

Wayfair

Zoom Video

These stocks are ignoring everything from valuation to coronavirus risks, and are instead pushing to new highs

10 High-Risk Stocks Flexing on the Market

Lingering disappointment over results announced on Tuesday and an FDA update are weighing on the stock.

Why Inovio Pharmaceuticals Stock Is Crashing Today

Shares of Inovio Pharmaceuticals Inc. INO, -17.92% declined 15.3% in trading on Wednesday after Maxim Group downgraded the stock to hold from buy.

Maxim downgrades Inovio, saying coronavirus opportunity is already 'priced in'

Inovio Pharmaceuticals Inc (NASDAQ: INO) reported Tuesday interim Phase 1 readout for INO-4800, its DNA vaccine candidate against the novel coronavirus.

Inovio's Manufacturing, Scalability Concerns Of Coronavirus Vaccine Keeps This Analyst On The Sidelines

Shares of biotech company Inovio Pharmaceuticals (INO) fell sharply on Tuesday after announcing updates to its Covid-19 vaccine candidate, INO-4800.

Why Inovio Pharmaceuticals Plunged 20% Today

SPDR Gold Trust

Micron Technology

Uber

Barrick Gold

Micron, the gold ETF, Barrick Gold, Inovio and Uber were our top stock trades for Wednesday. That said, let's look at the charts now.

5 Top Stock Trades for Wednesday: GLD, MU, GOLD, INO, UBER

Inovio Pharmaceuticals said Tuesday its potential coronavirus vaccine stoked an immune response in 94% of participants. But INO stock crumbled on vague antibody and T cell response data.

This Top Covid-19 Play Just Crumbled On Vague Coronavirus Vaccine Data

A Benchmark Research analyst expects that the Food and Drug Administration will allow Inovio Pharmaceuticals Inc.

Benchmark analyst expects FDA to allow Inovio's coronavirus vaccine to move to Phase 2/3 clinical

Inovio Pharmaceuticals Inc. (NASDAQ: INO) is one company that hopes to win big in the fight against coronavirus.

Why ‘Positive Results’ in Coronavirus Are Not Good Enough for Inovio Pharma

AstraZeneca

Moderna

The Food and Drug Administration (FDA) issued new rules on Tuesday for the companies developing COVID-19 vaccines. "While the FDA is committed to help expedite this work, we will not cut corners in our decision making, and we're making clear in our guidance what are the data that we need, that should be submitted, to meet our regulatory standards of approval," FDA commissioner Dr.

FDA issues rules for coronavirus vaccine developers

The results for INO-4800 were positive, but it’s much too early to celebrate.

Inovio Pharmaceuticals Reports Results From Phase 1 Clinical Trial of Coronavirus Vaccine Candidate

The biotech's "positive" results from an early-stage study weren't positive enough for investors.

Why Inovio Pharmaceuticals Stock Is Sinking Today

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares were moving to the downside Tuesday after the vaccine maker released interim Phase 1 data for the study that is evaluating its DNA vaccine INO-4800 against SARS-CoV-2, the virus that causes COVID-19.

Inovio Plunges On Interim Phase 1 Coronavirus Data; DNA Vaccine Shows 94% Response Rate

Royalty Pharma

Sanofi

Spain's Pharma Mar is looking at listing on New York's Nasdaq market, joining a flurry of biotech companies aiming to tap investors' voracious appetite for the sector as it tests one of its therapies to treat COVID-19.

Nasdaq's $1.2 trillion biotech index draws Europe's COVID drug hunters

Shares of Inovio Pharmaceuticals Inc. INO, +5.70% tumbled 10.8% in premarket trading on Tuesday after the company said its COVID-19 vaccine candidate was considered safe and well-tolerated in all 40 of the participants in a Phase 1 clinical trial.

Inovio's stock falls as it discloses early-stage data for its COVID-19 vaccine candidate

PLYMOUTH MEETING, Pa., June 30, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to protect and treat people from infectious diseases and cancer, today announced positive interim clinical data of...

INOVIO Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares have rallied strongly in late June, moving from $14.27 on June 19 to $31.25 on July 25, translating to a stellar gain of about 110%.

Inovio Analyst Downgrades COVID-19 Vaccine Developer, Says Risk Higher After Rally

Vaxart

After an unbelievable week, Investors want to know if these drugmakers have what it takes to keep climbing.

2 Biotech Stocks That Rocketed Higher Last Week

Despite amazing run-ups, these two biotech stocks are too risky to buy right now.

2 Coronavirus Vaccine Stocks to Avoid Right Now

One analyst thinks the biotech's shares have come too far too fast.

Why Inovio Stock Fell Today

Covid-19 vaccine stocks are red-hot right now thanks to the emergence of a second wave, but I'd be careful chasing this rally in INO stock.
The post Tread Carefully With INO Stock, Because Inovio Is Far From a Sure Thing appeared first on InvestorPlace.

News for Inovio Pharmaceuticals Stock (INO)